Sentinel Lymph Node Technique in Multifocal Breast Cancer
IGASSU
Interest of Sentinel Lymph Node Technique in Women With a Multifocal Breast Cancer - IGASSU-0502
1 other identifier
interventional
216
1 country
20
Brief Summary
The scope of this trial is to assess the Sentinel Lymph Node Technique in Multifocal Breast Cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2 breast-cancer
Started Mar 2006
Typical duration for phase_2 breast-cancer
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2006
CompletedFirst Submitted
Initial submission to the registry
December 29, 2006
CompletedFirst Posted
Study publicly available on registry
January 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 13, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
August 13, 2010
CompletedMarch 16, 2026
March 1, 2026
4.5 years
December 29, 2006
March 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
detection rate of sentinel nodes
surgery
Secondary Outcomes (2)
number of sentinel nodes removed
surgery
localisation of the sentinel nodes
surgery
Interventions
Eligibility Criteria
You may qualify if:
- Multifocal invasive breast cancer
- At least 2 focuses (clinically and/or by mammography or ultrasound)
- Proven by pre-surgical histology (on 1 focus at least)
- Age \> 18 years old
- Clinically negative axillary lymph nodes
- No treatment before surgery
- Signature of written informed consent
You may not qualify if:
- Multifocality proven after surgery
- Non invasive breast cancer
- Inflammatory breast cancer
- Axillary lymph node
- Metastatic disease
- Previous homolateral breast cancer
- Dementia or alterated mental status
- Pregnant or lactating woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (20)
Centre Hospitalier Universitaire
Amiens, 80054, France
Centre Paul Papin
Angers, 49933, France
Institut Bergonie
Bordeaux, 33076, France
Centre Jean Perrin
Clermont-Ferrand, 63011, France
Clinique de Flandre
Coudekerque-Branche, 59210, France
Centre Georges-Francois LECLERCQ
Dijon, 21000, France
Centre Oscar Lambret
Lille, 59020, France
Centre Leon Berard
Lyon, 69373, France
Institut Paoli Calmettes
Marseille, 130009, France
CRLC Val d'Aurelle
Montpellier, 34298, France
Hôpital Lariboisière
Paris, 75010, France
Hopital Tenon
Paris, 75970, France
Centre Eugene Marquis
Rennes, 35042, France
Centre Henri Becquerel
Rouen, 76038, France
Centre Rene Gauducheau
Saint-Herblain, 44805, France
Centre Hospitalier Sud Léman Valsérine
Saint-Julien-en-Genevois, 74167, France
Hôpital Georges PIANTA
Thonon-les-Bains, 74203, France
Centre Claudius Regaud
Toulouse, 31052, France
Centre Hospitalier
Valenciennes, 59300, France
Institut Gustave Roussy
Villejuif, 94808, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
GIARD Sylvia, MD
Centre Oscar Lambret
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 29, 2006
First Posted
January 1, 2007
Study Start
March 1, 2006
Primary Completion
August 13, 2010
Study Completion
August 13, 2010
Last Updated
March 16, 2026
Record last verified: 2026-03